This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Featured insights

  • 2014 Global health care outlook
    The global health care industry is undergoing a period of “glocalization,” a term that combines “globalization” and “localization” to describe the adaptation of global products or services to accommodate the needs of people in a specific locale.
  • 2014 Global life sciences outlook
    Despite heightened regulatory scrutiny, continued pricing pressures and another year of impacts from health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention.
  • Healthcare 3.0: Healthcare for the new normal
    The human body is a complex system which owes its continued survival to the fact that individual component organs are simultaneously working independently, and yet in unison in a fully integrated and synergistic manner within a self-regulated environment. Deloitte draws a parallel to this metaphor to illustrate key areas within the Healthcare 3.0 model and provide insights on the future and evolving state of healthcare.
  • Shaping the Future: From Meaningful Use to Meaningful User
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.
  • R&D value measurement: Is R&D earning its investment?
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement to learn more about how pharmaceutical innovation is facing a fundamental productivity challenge.
  • Pharmacovigilance: Alert and on guard
    Over the past decade, a series of adverse drug safety-related events have led to increased scrutiny and drug safety monitoring regulations. The business case for building strong, efficient pharmacovigilance organisations has never been better.
  • Value-based Pricing for Pharmaceuticals
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialisation and pricing. This Issue Brief summarises what is known to date about value-based pricing and identifies opportunities for additional exploration.

Featured insights

  • 2014 Global health care outlook
    The global health care industry is undergoing a period of “glocalization,” a term that combines “globalization” and “localization” to describe the adaptation of global products or services to accommodate the needs of people in a specific locale.
  • 2014 Global life sciences outlook
    Despite heightened regulatory scrutiny, continued pricing pressures and another year of impacts from health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention.
  • Healthcare 3.0: Healthcare for the new normal
    The human body is a complex system which owes its continued survival to the fact that individual component organs are simultaneously working independently, and yet in unison in a fully integrated and synergistic manner within a self-regulated environment. Deloitte draws a parallel to this metaphor to illustrate key areas within the Healthcare 3.0 model and provide insights on the future and evolving state of healthcare.
  • Shaping the Future: From Meaningful Use to Meaningful User
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.
  • R&D value measurement: Is R&D earning its investment?
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement to learn more about how pharmaceutical innovation is facing a fundamental productivity challenge.
  • Pharmacovigilance: Alert and on guard
    Over the past decade, a series of adverse drug safety-related events have led to increased scrutiny and drug safety monitoring regulations. The business case for building strong, efficient pharmacovigilance organisations has never been better.
  • Value-based Pricing for Pharmaceuticals
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialisation and pricing. This Issue Brief summarises what is known to date about value-based pricing and identifies opportunities for additional exploration.

Featured insights

  • 2014 Global health care outlook
    The global health care industry is undergoing a period of “glocalization,” a term that combines “globalization” and “localization” to describe the adaptation of global products or services to accommodate the needs of people in a specific locale.
  • 2014 Global life sciences outlook
    Despite heightened regulatory scrutiny, continued pricing pressures and another year of impacts from health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention.
  • Healthcare 3.0: Healthcare for the new normal
    The human body is a complex system which owes its continued survival to the fact that individual component organs are simultaneously working independently, and yet in unison in a fully integrated and synergistic manner within a self-regulated environment. Deloitte draws a parallel to this metaphor to illustrate key areas within the Healthcare 3.0 model and provide insights on the future and evolving state of healthcare.
  • Shaping the Future: From Meaningful Use to Meaningful User
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.
  • R&D value measurement: Is R&D earning its investment?
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement to learn more about how pharmaceutical innovation is facing a fundamental productivity challenge.
  • Pharmacovigilance: Alert and on guard
    Over the past decade, a series of adverse drug safety-related events have led to increased scrutiny and drug safety monitoring regulations. The business case for building strong, efficient pharmacovigilance organisations has never been better.
  • Value-based Pricing for Pharmaceuticals
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialisation and pricing. This Issue Brief summarises what is known to date about value-based pricing and identifies opportunities for additional exploration.

Featured insights

  • 2014 Global health care outlook
    The global health care industry is undergoing a period of “glocalization,” a term that combines “globalization” and “localization” to describe the adaptation of global products or services to accommodate the needs of people in a specific locale.
  • 2014 Global life sciences outlook
    Despite heightened regulatory scrutiny, continued pricing pressures and another year of impacts from health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention.
  • Healthcare 3.0: Healthcare for the new normal
    The human body is a complex system which owes its continued survival to the fact that individual component organs are simultaneously working independently, and yet in unison in a fully integrated and synergistic manner within a self-regulated environment. Deloitte draws a parallel to this metaphor to illustrate key areas within the Healthcare 3.0 model and provide insights on the future and evolving state of healthcare.
  • Shaping the Future: From Meaningful Use to Meaningful User
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.
  • R&D value measurement: Is R&D earning its investment?
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement to learn more about how pharmaceutical innovation is facing a fundamental productivity challenge.
  • Pharmacovigilance: Alert and on guard
    Over the past decade, a series of adverse drug safety-related events have led to increased scrutiny and drug safety monitoring regulations. The business case for building strong, efficient pharmacovigilance organisations has never been better.
  • Value-based Pricing for Pharmaceuticals
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialisation and pricing. This Issue Brief summarises what is known to date about value-based pricing and identifies opportunities for additional exploration.

Featured insights

  • 2014 Global health care outlook
    The global health care industry is undergoing a period of “glocalization,” a term that combines “globalization” and “localization” to describe the adaptation of global products or services to accommodate the needs of people in a specific locale.
  • 2014 Global life sciences outlook
    Despite heightened regulatory scrutiny, continued pricing pressures and another year of impacts from health care reform in many countries, the global life sciences sector is exhibiting resilience and reinvention.
  • Healthcare 3.0: Healthcare for the new normal
    The human body is a complex system which owes its continued survival to the fact that individual component organs are simultaneously working independently, and yet in unison in a fully integrated and synergistic manner within a self-regulated environment. Deloitte draws a parallel to this metaphor to illustrate key areas within the Healthcare 3.0 model and provide insights on the future and evolving state of healthcare.
  • Shaping the Future: From Meaningful Use to Meaningful User
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.
  • R&D value measurement: Is R&D earning its investment?
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement to learn more about how pharmaceutical innovation is facing a fundamental productivity challenge.
  • Pharmacovigilance: Alert and on guard
    Over the past decade, a series of adverse drug safety-related events have led to increased scrutiny and drug safety monitoring regulations. The business case for building strong, efficient pharmacovigilance organisations has never been better.
  • Value-based Pricing for Pharmaceuticals
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialisation and pricing. This Issue Brief summarises what is known to date about value-based pricing and identifies opportunities for additional exploration.
Stay connected:
More on Deloitte
Learn about our site